BIOLASE, INC
Healthcare · Dental Equipment & Supplies · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $49.2M | $48.5M | $39.2M | $22.8M | $37.8M | $46.2M |
| Operating income | −$17.9M | −$25.3M | −$16.4M | −$18.5M | −$15.6M | −$20.9M |
| Net income | −$20.6M | −$28.6M | −$16.2M | −$16.8M | −$17.9M | −$21.5M |
| Total assets | $35.1M | $38.2M | $55.3M | $41.0M | $31.8M | $38.5M |
| Total liabilities | $33.1M | $33.3M | $30.1M | $31.0M | $27.5M | $27.4M |
| Equity | −$247,000 | $4.9M | $25.2M | $10.0M | $377,000 | $11.1M |
| EPS (diluted) | $-29.44 | $-418.13 | $-283.12 | $-0.56 | $-0.77 | $-1.05 |
| Shares out. | 26.33B | 154.3M | 149.4M | 31.6M | 21.1M | 102.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −36.5%
- Net margin
- −42.0%
- Return on equity
- 8353.0%
- Return on assets
- −58.8%
- Return on capital (ROCE)
- −116.2%
- Liabilities / assets
- 94.4%
- Debt / equity
- —
- Book value / share
- $-0.00
- Revenue growth (YoY)
- 1.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -31.89distress
- Accruals / assets
- −18.6%clean
- Beneish M-Score
- -3.49normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeOct 8, 2024
- Entered a material agreement · Bankruptcy or receivership · Debt acceleration / triggering event · Other material eventOct 1, 2024
- Entered a material agreement · Delisting / listing-standard noticeSep 6, 2024
- Debt acceleration / triggering eventAug 28, 2024
- Results of operationsAug 8, 2024
- Unregistered equity saleJul 22, 2024
- Delisting / listing-standard noticeJun 18, 2024
- Delisting / listing-standard noticeMay 17, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.